Preferred Label : mRNA-derived IDO/PD-L1-targeted Vaccine mRNA-4359;
NCIt definition : A mRNA-based cancer vaccine that targets the immunomodulatory enzyme indoleamine 2,3-dioxygenase
(IDO; IDO1) and the tumor-associated antigen (TAA) and immune checkpoint molecule
programmed cell death-1 ligand 1 (PD-L1), with potential immunostimulatory and antineoplastic
activities. Upon intramuscular administration, the mRNA-derived IDO/PD-L1-targeted
vaccine mRNA-4359 is taken up and translated by antigen presenting cells (APCs). Following
translation, the epitopes are presented via major histocompatibility complex (MHC)
molecules on the surface of the APCs. This leads to an induction of cytotoxic T-lymphocyte
(CTL)-mediated immune response that specifically targets and destroys tumor cells
and immunosuppressive cells expressing IDO and PD-L1. This may restore the proliferation
and activation of various immune cells, and may eradicate tumor cells expressing IDO
and PD-L1. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion
of tryptophan into kynurenine, is overexpressed on multiple tumor cell types as well
as on APCs. Tryptophan depletion inhibits T-lymphocyte proliferation and activation,
and subsequently suppresses the immune system. PD-L1 is overexpressed on many tumor
cell types as well as on APCs and immunosuppressive cells in the tumor micro-environment
(TME), such as regulatory T-cells (Tregs). PD-L1 binding to its cognate receptor programmed
cell death protein 1 (PD-1; PDCD1; CD279) on T-cells suppresses the immune system
and results in increased immune evasion and decreased CTL activation.;
Molecule name : mRNA-4359; mRNA 4359;
NCI Metathesaurus CUI : CL1799377;
Origin ID : C190738;
UMLS CUI : C5783895;
Semantic type(s)
- concept_is_in_subset
- has_target
